Prevention and treatment of complement-associated disorders
AssigneeGenentech, Inc.
InventorsAvi Ashkenazi, Karim Helmy, Sherman Fong, Audrey Goddard, Austin Gurney, Kenneth Katschke, Menno Lookeren, William Wood
Life of this patent
Estimating the term…
Abstract
The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the prevention and treatment of complement-associated disorders, including complement-associated eye conditions, such as age-related macular degeneration (AMD) and choroidal neovascularization (CNV).
Claims82
A method for the prevention or treatment of a complement-associated eye condition, comprising administering to a subject in need a prophylactically or therapeutically effective amount of a complement inhibitor.
The method of claim I wherein said complement inhibitor is a selective inhibitor of the alternative complement pathway.
The method of claim I wherein the complement-associated eye condition is selected from the group consisting of age-related macular degeneration (AMD), choroidal neovascularization (CNV), uveitis, diabetic and other ischemia-related retinopathies, endophthalmitis, diabetic macular edema, pathological myopia, von Hippel-Lindau disease, histoplasmosis of the eye, Central Retinal Vein Occlusion (CRVO), corneal neovascularization, and retinal neovascularization.
A method for the prevention of the development or progression of age-related macular degeneration (AMD), comprising administering to subject at risk of developing or diagnosed with AMD in at least one eye, an effective amount of a CRIg polypeptide or an agonist thereof.
A method for the treatment of dry age-related macular degeneration (AMD), comprising administering to a subject in need a prophylactically or therapeutically effective amount of a CRIg polypeptide or an agonist thereof.
A method for the prevention or treatment of a complement-associated diseases or condition, comprising treating a subject in need of such treatment with a prophylactially or therapeutically effective amount of a CRIg polypeptide or an agonist thereof.
A method for inhibition of the production of C3b complement fragment in a mammal comprising administering to said mammal an effective amount of a CRIg polypeptide or an agonist thereof.
A method for selective inhibition of the alternative complement pathway in a mammal, comprising administering to said mammal an effective amount of CRIg polypeptide or an agonist thereof.
Dependencies are inferred from the claim text.